{
    "clinical_study": {
        "@rank": "111036", 
        "acronym": "Dox/Urso", 
        "arm_group": {
            "arm_group_label": "Doxycycline and UDCA", 
            "arm_group_type": "Experimental", 
            "description": "Doxycycline (200 mg/day intermittently) and UDCA (750 mg/day continuously)"
        }, 
        "brief_summary": {
            "textblock": "The primary objective for this study is to evaluate the efficacy of doxycycline +\n      ursodeoxycholic acid (UDCA) on disease progression in Transthyretin Amyloidosis (ATTR)\n      subjects with cardiomyopathy with or without neuropathy."
        }, 
        "brief_title": "Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Transthyretin Amyloidosis", 
            "Cardiomyopathy"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Amyloidosis", 
                "Disease Progression", 
                "Cardiomyopathies"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Cardiomyopathy with septal thickness > 15 mm and/or S-NT-ProBNP > 300 ng/\n\n          -  Age >50 years\n\n          -  Male and females after menopause. Menopause is defined as 6 to 12 months of\n             amenorrhea in a woman over 45 years of age.\n\n          -  Written informed consent to be obtained prior to any study procedure\n\n          -  Histochemical diagnosis of amyloidosis as based on detection by polarizing microscopy\n             of green birefringent material in Congo red-stained tissue specimens, and typing of\n             amyloid deposits as TTR and identification of amyloid fibril type.\n\n          -  Molecular definition of the TTR mutation or immunohistochemical staining of amyloid\n             fibrils with anti TTR antibody\n\n          -  New York Heart Association (NYHA) class <III\n\n          -  Systolic blood pressure >100 mmHg (standing)\n\n          -  Must have symptomatic organ involvement with amyloid to justify therapy\n\n        Exclusion Criteria:\n\n          -  Liver transplantation in the previous 6 months or liver transplantation anticipated\n             in less than 6 months;\n\n          -  ALT and/or AST > 2 x upper normal limit (UNL);\n\n          -  Creatinine clearance < 30 ml/min (Cockcroft -Gault Formula)\n\n          -  Any other lab values, illness or condition that in the opinion of the investigator\n             might place the subject at unacceptable risk for participation in the study;\n\n          -  History of hypersensitivity to any of the ingredients of the study therapies;\n\n          -  Use of any investigational drug, device (or biologic) within 4 weeks prior to study\n             entry or during the study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02016365", 
            "org_study_id": "EudraCT No:2011-005236-25"
        }, 
        "intervention": [
            {
                "arm_group_label": "Doxycycline and UDCA", 
                "description": "200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA", 
                "intervention_name": "Doxycycline", 
                "intervention_type": "Drug", 
                "other_name": "Doxyferm"
            }, 
            {
                "arm_group_label": "Doxycycline and UDCA", 
                "description": "750 mg/day (500 mg +250mg orally) continuously", 
                "intervention_name": "Ursodeoxycholic acid", 
                "intervention_type": "Drug", 
                "other_name": "Ursofalk"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Doxycycline", 
                "Doxycycline hyclate", 
                "Ursodeoxycholic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Transthyretin amyloidosis", 
            "Cardiomyopathy", 
            "ATTR", 
            "neuropathy"
        ], 
        "lastchanged_date": "December 13, 2013", 
        "location": [
            {
                "contact": {
                    "email": "Katarzyna.Liszewska@nll.se", 
                    "last_name": "Katarzyna Liszewska, MD", 
                    "phone": "0911 - 750 00", 
                    "phone_ext": "232"
                }, 
                "facility": {
                    "address": {
                        "city": "Pite\u00e5", 
                        "country": "Sweden", 
                        "zip": "SE-941 28"
                    }, 
                    "name": "Dept of Clinical Medicin, Ptie\u00e5 Hospital"
                }, 
                "investigator": {
                    "last_name": "Katarzyna Liszewska, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lars.wikstrom@vll.se", 
                    "last_name": "Lars Wikstr\u00f6m, MD", 
                    "phone": "+46 910-7710 00", 
                    "phone_ext": "1667"
                }, 
                "facility": {
                    "address": {
                        "city": "Skellefte\u00e5", 
                        "country": "Sweden", 
                        "zip": "SE-931 86"
                    }, 
                    "name": "Dept of clinical medicin, Skellefte\u00e5 Hospital"
                }, 
                "investigator": {
                    "last_name": "Lars Wikstr\u00f6m, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "marjaliisa.lammitavelin@vll.se", 
                    "last_name": "Marja-Liisa Lammi Tavelin, MSc", 
                    "phone": "+46 90 785 8039"
                }, 
                "facility": {
                    "address": {
                        "city": "Ume\u00e5", 
                        "country": "Sweden", 
                        "zip": "SE-90185"
                    }, 
                    "name": "Dept of Clinical Medicine, Ume\u00e5 University Hospital"
                }, 
                "investigator": {
                    "last_name": "Ole B Suhr, MD PhD Prof", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Sweden"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Multicenter Pilot Study of the Safety and Efficacy of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis", 
        "overall_contact": {
            "email": "ole.suhr@medicin.umu.se", 
            "last_name": "Ole B Suhr, MD PhD Prof", 
            "phone": "+46 732-670 762"
        }, 
        "overall_official": {
            "affiliation": "Dept of Clinical Medicine  and public Health, Ume\u00e5 University", 
            "last_name": "Ole B Suhr, MD PhD Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint of the study is the response rate to doxycycline + UDCA treatment at month 12. A responder is an ATTR subject with:\n- a reduction of, or an  increase in serum NT-proBNP concentration of less than 30% of pre-treatment level will be regarded as consistent with treatment efficacy", 
            "measure": "The efficacy on serum N terminal proBNP (NT-proBNP)", 
            "safety_issue": "No", 
            "time_frame": "At 12 month treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02016365"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Ume\u00e5 University", 
            "investigator_full_name": "Ole B Suhr, Professor, MD, PhD", 
            "investigator_title": "Professor, MD, PhD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "mBMI-reduction of less than 10%", 
                "measure": "Modified Body Mass Index (mBMI) reduction", 
                "safety_issue": "No", 
                "time_frame": "12 month"
            }, 
            {
                "description": "Increase of septum thickness \u2264 2 mm", 
                "measure": "Increase of septum thickness", 
                "safety_issue": "No", 
                "time_frame": "12 month"
            }, 
            {
                "description": "To assess the change from baseline in the neurologic Kumamoto Scale", 
                "measure": "Neurologic Kumamoto Scale", 
                "safety_issue": "No", 
                "time_frame": "6, 12 and 18 month"
            }, 
            {
                "description": "To assess the tolerability and safety of the treatment, the number of patients with adverse reactions will be recorded.\nMonthly phone contacts will be performed for monitoring of the treatment safety.\nThe safety profile of doxycycline + UDCA will be assessed through the recording, reporting and analysis of baseline medical conditions, physical examination findings including vital signs and laboratory tests. These will be compared to analysis results observed during the study.", 
                "measure": "Number of patients with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "During 12 month treatment and during 6 month follow-up"
            }, 
            {
                "description": "To assess the tolerability and safety of the treatment, blood work [e.g.complete blood count, creatinine and aspartate transaminase (AST), alkaline phosphatase(ALT)] for potential drug-related adverse events will be drawn at 1, 3, 6, 9, 12 and 18 month.\nThe safety profile of doxycycline + UDCA will be assessed through the recording, reporting and analysis of baseline medical conditions, physical examination findings including vital signs and laboratory tests. These will be compared to analysis results observed during the study.", 
                "measure": "Blood work for potential drug-related adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Ume\u00e5 University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ume\u00e5 University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}